» Articles » PMID: 17261405

Chronic Kidney Disease Associated Mortality in Diastolic Versus Systolic Heart Failure: a Propensity Matched Study

Overview
Journal Am J Cardiol
Date 2007 Jan 31
PMID 17261405
Citations 114
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic kidney disease (CKD) is common and is associated with increased mortality in heart failure (HF). However, it is unknown whether the effect of CKD on mortality varies by left ventricular ejection fraction (LVEF). We evaluated the effect of CKD on mortality in patients with systolic (LVEF <or=45%) and diastolic (LVEF >45%) HF. Of the 7,788 patients in the Digitalis Investigation Group trial, 3,527 (45%) had CKD (estimated glomerular filtration rate <60 ml/min/1.73 m2). We calculated the propensity score for CKD for each patient, using a multivariate logistic regression model (c statistic 0.76, postmatch absolute standardized differences <5% for all 32 co-variates). We matched 2,399 pairs of patients with and without CKD with similar propensity scores. There were 757 (rate 1,049/10,000 person-years) and 882 (rate 1,282/10,000 person-years) deaths, respectively, in patients without and with CKD (hazard ratio 1.22, 95% confidence interval 1.09 to 1.36, p <0.0001). CKD-associated mortality was higher in those with diastolic HF (371 extra deaths/10,000 person-years, hazard ratio 1.71, 95% confidence interval 1.21 to 2.41, p = 0.002) than in systolic HF (214 extra deaths/10,000 person-years, hazard ratio 1.19, 95% confidence interval 1.07 to 1.32, p = 0.001), which was significant (adjusted p for interaction = 0.034). A graded association was found between CKD-related deaths and LVEF. The hazard ratios for CKD-associated mortality for the LVEF subgroups of <35%, 35% to 55%, and >55% were 1.15 (95% confidence interval 1.02 to 1.29), 1.35 (95% confidence interval 1.11 to 1.64), and 2.33 (95% confidence interval 1.34 to 4.06). In conclusion, CKD-associated mortality was higher in those with diastolic than systolic HF. Patients with diastolic HF should be evaluated for CKD, and the role of inhibitors of the renin-angiotensin system in these patients needs to be investigated.

Citing Articles

Peripheral artery disease, chronic kidney disease, and recurrent admissions for acute decompensated heart failure: The ARIC study.

Chunawala Z, Bhatt D, Qamar A, Vaduganathan M, Mentz R, Matsushita K Atherosclerosis. 2024; 395:118521.

PMID: 38968642 PMC: 11382611. DOI: 10.1016/j.atherosclerosis.2024.118521.


Potential Effects of Digoxin on Renal Functions in Patients With Congestive Heart Failure.

Alqahtani M, Alqahtani B, Dighriri I Cureus. 2023; 15(9):e45419.

PMID: 37854741 PMC: 10581505. DOI: 10.7759/cureus.45419.


Cardiorenal Syndrome: A Literature Review.

Ajibowo A, Okobi O, Emore E, Soladoye E, Sike C, Odoma V Cureus. 2023; 15(7):e41252.

PMID: 37529809 PMC: 10389294. DOI: 10.7759/cureus.41252.


Matrix metalloproteinase-9 regulates afferent arteriolar remodeling and function in hypertension-induced kidney disease.

Feng W, Guan Z, Ying W, Xing D, Ying K, Sanders P Kidney Int. 2023; 104(4):740-753.

PMID: 37423509 PMC: 10854403. DOI: 10.1016/j.kint.2023.06.031.


How to Use Natriuretic Peptides in Patients with Heart Failure with Non-Reduced Ejection Fraction?.

Celik A, Kilicaslan B, Temizhan A, Guvenc T, Altay H, Cavusoglu Y Anatol J Cardiol. 2023; 27(6):308-318.

PMID: 37257015 PMC: 10250766. DOI: 10.14744/AnatolJCardiol.2023.3297.


References
1.
McAlister F, Ezekowitz J, Tonelli M, Armstrong P . Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004; 109(8):1004-9. DOI: 10.1161/01.CIR.0000116764.53225.A9. View

2.
Collins J, Howell C, Horney R . Determination of vital status at the end of the DIG trial. Control Clin Trials. 2003; 24(6):726-30. DOI: 10.1016/j.cct.2003.08.011. View

3.
Curtis J, Sokol S, Wang Y, Rathore S, Ko D, Jadbabaie F . The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol. 2003; 42(4):736-42. DOI: 10.1016/s0735-1097(03)00789-7. View

4.
Ahmed A, Perry G, Fleg J, Love T, Goff Jr D, Kitzman D . Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis. Am Heart J. 2006; 152(5):956-66. PMC: 2628474. DOI: 10.1016/j.ahj.2006.06.020. View

5.
Ahmed A, Kiefe C, Allman R, Sims R, DeLong J . Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc. 2002; 50(10):1659-66. DOI: 10.1046/j.1532-5415.2002.50457.x. View